The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

(Reuters) – The U.S. Food and Drug Administration (FDA) said on Friday it approved Novartis AG’s treatment in combination with hormone therapy fulvestrant for postmenopausal women, as well as men, with a form of advanced breast cancer.

The drug, alpelisib, to be marketed with the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors and is the first of its kind to be approved, the FDA said in a statement.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva


READ  Hospitals will publish yearly dossier of dodgy deaths under new law aimed at detecting serial killers in the NHS


Please enter your comment!
Please enter your name here